Astellas Bladder Treatment Wins U.S. Approval for Sale
Posted on July 2, 2012
Astellas Pharma Inc. won approval
for its overactive bladder treatment aimed at an estimated 33
million Americans who suffer from the condition.
Dr. Whang Comments:
There are already 7 or more medications (anticholinergic medications) approved by the FDA for treatment of overactive bladder (OAB). There are several side effects of the anticholinergic medications including dry mouth, constipation, sedation and urinary retention. In men with an enlarged prostate (BPH) and overactive bladder, urinary retention ( inability to void) is a significant concern. This new medication (Myrbetriq) claims to have less risk of urinary retention. If true, it would be a great advantage for men with BPH and overactive bladder. It does have some significant side effects including increased heart rate and high blood pressure. As a result, Myrbetriq isn’t recommended for use in those with severe uncontrolled high blood pressure, end-stage kidney disease or severe liver impairment.
Posted in Uncategorized